← Novo Nordisk A/S overview

Novo Nordisk A/S vs Novartis: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novo Nordisk A/S (NVO)

Q3 2026
▼3▲1

Novo Nordisk's Q3: Pipeline Wins Offset by Trial Failures and Lilly's Lead

  • Pipeline Expansion and Licensing Deals Novo advanced its pipeline with EU approval of oral Wegovy, German rollout, China MASH approval, and later-phase CagriSema superiority wins. Licensing deals worth up to $4 billion aim to rebuild its pipeline.

    These positive developments show progress in expanding product reach and pipeline, potentially supporting future growth.

  • Clinical Setbacks and Competitive Losses Ziltivekimab failed Phase 3, CagriSema missed goals versus Lilly's Zepbound, and oral Wegovy sales disappointed. Lilly captured 60% obesity share and over 30% of new US oral GLP-1 patients.

    These setbacks and competitive losses directly hurt Novo's market position and investor confidence.

  • Coverage Cuts and Analyst Downgrade US employers cut coverage for obesity drugs, and Morgan Stanley downgraded Novo citing the 2032 semaglutide patent cliff. Capital Markets Day targets disappointed investors.

    Reduced coverage and downgrades reflect concerns about future revenue and patent expiration.

  • Generic Challenge to Wegovy Viatris filed a generic challenge to Wegovy, threatening Novo's market exclusivity and pricing power in the US.

    A generic challenge could erode Novo's sales and market share if successful.

September 2026
▼6▲5

September brings more setbacks than wins for Novo Nordisk

  • CagriSema misses head-to-head goals versus Lilly's Zepbound Novo's next-generation obesity drug CagriSema failed to match Eli Lilly's Zepbound in head-to-head trials, weakening Novo's ability to win back market share and raising doubts about its pipeline.

    This is a major competitive setback that directly threatens Novo's future obesity franchise.

  • Two more ziltivekimab heart trials halted Two additional heart trials for ziltivekimab were stopped, adding to safety and efficacy concerns for a drug Novo hoped would diversify beyond diabetes and obesity.

    Halting trials signals pipeline risk and potential delays, weighing on investor confidence.

  • Morgan Stanley downgrades on semaglutide 2032 patent cliff Morgan Stanley downgraded Novo Nordisk stock, citing the upcoming 2032 patent expiration for semaglutide, which could open the door to generic competition and pressure future sales.

    A major analyst downgrade highlights long-term revenue risks and can influence investor sentiment.

  • Lilly's Foundayo captures over 30% of new US oral GLP-1 patients Eli Lilly's oral GLP-1 drug Foundayo quickly gained more than 30% of new US oral GLP-1 patients, eroding Novo's first-mover advantage in the oral obesity market.

    This shows rapid competitive share loss in a key growth area for Novo.

  • Capital Markets Day disappoints; shares fall 6% on unambitious 2030 targets Novo's Capital Markets Day failed to impress, with shares dropping 6% as the company's 2030 targets were seen as unambitious, raising concerns about growth prospects.

    The market's negative reaction to strategic guidance directly impacted the stock price.

  • Viatris files generic Wegovy challenge Viatris filed a legal challenge to produce a generic version of Wegovy, threatening Novo's key obesity drug franchise with early competition and potential revenue loss.

    A generic challenge could accelerate price erosion and market share loss for Novo's flagship product.

  • CagriSema later phase 3 superiority wins Despite earlier head-to-head misses, CagriSema achieved superiority in later phase 3 trials, offering a potential path to regain competitiveness in obesity treatment.

    This positive trial result provides a counterweight to the negative CagriSema news and supports pipeline hope.

  • EU approvals for Frehemgo and Sogroya Novo received European Union approvals for Frehemgo and Sogroya, expanding its product portfolio and opening new revenue streams in Europe.

    Regulatory approvals are concrete positive catalysts that can drive future sales.

  • Wegovy's German pill launch and China MASH approval Wegovy's oral pill launched in Germany and received approval for MASH in China, broadening access to key markets and supporting Novo's global expansion.

    Geographic expansion and new indications can boost demand and offset competitive pressures.

  • Strong oral Wegovy real-world data Real-world data for oral Wegovy showed strong performance, reinforcing its efficacy and supporting continued adoption despite competitive entries.

    Positive real-world evidence can bolster physician and patient confidence, aiding sales.

  • Up to $4 billion in licensing deals (Hengrui, Orbis, Nanexa) to rebuild pipeline Novo signed licensing deals worth up to $4 billion with Hengrui, Orbis, and Nanexa, aiming to replenish its pipeline and secure future growth opportunities.

    These deals demonstrate proactive efforts to address pipeline gaps and could improve long-term prospects.

Latest
▲2▼2

Novo's pipeline rebuild offsets patent and Lilly threats

  • Semaglutide patent cliff confirmed Novo's CEO called the loss of semaglutide patent protection the 'elephant in the room', with US exclusivity ending in 2032. Since the US is over half of sales, this long-term revenue threat keeps a lid on the stock.

    This is the core structural risk that explains why the stock remains under pressure despite pipeline news.

  • Lilly widens competitive lead Lilly's Foundayo grabbed a third of new US oral GLP-1 patients, and indirect comparisons showed Foundayo and higher-dose Zepbound beating Novo's oral semaglutide and Wegovy on weight loss. This erodes Novo's pricing power in its biggest market.

    Directly shows Novo losing ground to its main rival in the obesity market, a key driver of the stock's underperformance.

  • Pipeline rebuild via licensing deals Novo signed deals worth up to $4 billion combined: $2.6 billion for Hengrui's oral GLP-1/GIP drug and $1.4 billion for Orbis's oral cardiometabolic platform. These add early-stage shots on goal to replace lost semaglutide sales.

    Shows Novo actively addressing its pipeline gap, a key investor concern, though benefits are years away.

  • Clinical data supports Wegovy franchise New data showed patients switching to oral Wegovy kept losing weight, and injectable Wegovy normalized liver fat in nearly 9 of 10 obese adults. Oral Wegovy now captures over 80% of new US oral prescriptions, reinforcing the franchise's durability.

    Provides evidence that Novo's existing products remain competitive and can defend market share.

▲2▼1

Novo's 2030 plan disappoints; pipeline and rare-disease wins offset generic threat

  • Capital Markets Day targets fail to impress Novo's first strategy update under new CEO Mike Doustdar set 2030 revenue growth only in line with peers and a broadly stable margin, with no formal guidance. Shares fell about 6% as investors wanted more ambition and clarity.

    This was the period's biggest price-moving event and frames the whole period.

  • CagriSema beats tirzepatide in phase 3 CagriSema delivered 12.4% weight loss versus 9.1% for tirzepatide in diabetes patients and 21% versus 2% for placebo in obesity, meeting superiority goals. This revives Novo's next-generation obesity drug ahead of a US approval decision due in late 2026.

    It directly counters earlier CagriSema disappointment and is a core pipeline catalyst.

  • Rare-disease and oral Wegovy data advance EU regulators backed Frehemgo for hemophilia A and once-weekly Sogroya for short stature, with launches expected from late 2026. A real-world study also showed oral Wegovy drives strong weight loss in patients who recently gained weight, supporting the pill's rollout.

    These are new revenue sources and data that broaden Novo beyond its pressured GLP-1 franchise.

  • Pipeline deals expand, but generic Wegovy challenge filed Novo licensed Nanexa's long-acting injection technology for up to $1.3 billion, aiming for monthly or quarterly obesity shots. Separately, Viatris sued to sell a generic Wegovy, though US semaglutide patents block generics until 2032.

    One deal strengthens the pipeline while the lawsuit tests the key patent wall protecting Novo's biggest product.

▼2▲1

Novo resets strategy as Lilly's pill erodes its oral GLP-1 lead

  • Lilly's Foundayo grabs 30% of new US oral patients Eli Lilly's oral obesity drug Foundayo has already captured over 30% of new US patients, eating into the early lead Novo built with its oral Wegovy pill. This directly threatens Novo's biggest growth product and its pricing power in the world's largest obesity market.

    This is the clearest new evidence that Novo's oral GLP-1 advantage is shrinking, a core driver of the stock.

  • Novo rebrands and resets as diabetes share slips Novo is rebranding to 'Novo' and launching a cultural reset under CEO Mike Doustdar, with its diabetes value-market share down 3.6 points and 2026 sales expected to fall 5-13%. The reset signals the company is on the back foot against Lilly, weighing on sentiment.

    The rebrand and strategy reset, plus the sales decline guidance, show the scale of the competitive problem Novo faces.

  • AI and biotech deals aim to rebuild the pipeline Novo partnered with Anthropic to use AI in drug research and signed a deal with Orbis Medicines worth up to $1.4 billion for next-generation oral cardiometabolic drugs. These early-stage moves could speed up new medicines, though they won't affect sales for years.

    These are new pipeline-building actions that offer a counterweight to the negative competitive news.

  • New EU approvals and a halted heart trial Novo won EU panel backing for Frehemgo in hemophilia A and for once-weekly Sogroya in children's growth, adding new revenue outside obesity. But it halted two more ziltivekimab heart trials after a July failure, further denting its diversification efforts.

    These regulatory wins and the trial halt show Novo's efforts to broaden beyond obesity are progressing unevenly.

▼3▲1

Novo's pipeline setbacks and patent cliff fears overshadow new market wins

  • CagriSema fails to beat Lilly's Zepbound in head-to-head trial Novo's next-generation obesity drug CagriSema delivered 23% weight loss versus Zepbound's 25.5%, missing the goal of being at least as good. This widens the gap with Eli Lilly and raises doubts about Novo's ability to close it, weighing on the stock.

    This is a major competitive setback that directly threatens Novo's future obesity franchise.

  • Novo halts two more heart drug trials, hurting diversification Novo stopped two additional trials of its heart drug ziltivekimab because they were unlikely to succeed, after a previous failure. This removes a potential new growth area beyond obesity and diabetes, making investors more cautious about Novo's pipeline.

    It shows Novo's efforts to diversify are failing, which increases reliance on semaglutide and adds to negative sentiment.

  • Morgan Stanley downgrades Novo to Underweight on patent cliff Morgan Stanley cut Novo to Underweight, warning that the coming loss of exclusivity on semaglutide will hurt long-term sales and that growth will lag European peers. The downgrade adds selling pressure and highlights a major overhang for the stock.

    This is a fresh analyst action that directly addresses the biggest long-term risk: the patent cliff.

  • Wegovy pill launches in Germany and wins new approval in China Novo launched its Wegovy pill in Germany, the first EU market, and China approved Wegovy for a liver disease called MASH. These expand the reach of semaglutide into new patients and geographies, offering fresh sales opportunities.

    These are concrete new market expansions that could partially offset competitive and pipeline pressures.

August 2026
▼4

Novo loses ground to Lilly as oral Wegovy misses and competition bites

  • CagriSema fails to match Lilly's Zepbound Novo's next-generation obesity drug CagriSema did not work as well as Eli Lilly's Zepbound in trials. This weakens Novo's ability to win back market share and raises doubts about its pipeline.

    A key pipeline disappointment that directly hurts Novo's competitive position.

  • Oral Wegovy sales miss twice; shares drop ~6% Sales of Novo's new oral Wegovy pill fell short of expectations twice in August, sending shares down about 6%. This suggests the pill is not yet making up for slowing injection sales.

    A direct negative for revenue expectations and investor confidence.

  • Lilly's Foundayo wins UK approval, ending oral GLP-1 exclusivity Eli Lilly's oral GLP-1 drug Foundayo was approved in the UK, ending Novo's exclusive hold on the oral GLP-1 market there. This opens the door to direct competition for oral Wegovy.

    A regulatory and competitive blow that erodes Novo's first-mover advantage.

  • US employers cut obesity-drug coverage; Lilly gains cost and heart-data edge More US employers are dropping coverage of obesity drugs, which could reduce demand. Meanwhile, Lilly's drugs have cost and heart-health data advantages, making it harder for Novo to compete.

    Highlights demand risk and competitive disadvantages that pressure Novo's sales.

▲2▼2

Novo's China Wegovy filing advances, but US coverage and Lilly threats weigh

  • China accepts oral Wegovy for regulatory review Chinese regulators accepted Novo's application for the oral Wegovy pill, opening the door to the world's second-biggest drug market where over 65% of people may be overweight by 2030. Approval is not guaranteed, but it gives Novo a new growth path as it tries to catch Lilly in China.

    This is the period's clearest new positive for Novo's future sales and directly answers what is driving the stock.

  • US employers plan to drop obesity drug coverage A survey found about 14% of US employers intend to stop covering GLP-1 obesity drugs by 2027, and the share of companies covering them already fell from 72% to 60%. Fewer insured patients means less demand for Wegovy, a direct hit to Novo's biggest US growth product.

    This is a new, concrete threat to US demand for Novo's core obesity drug, a key force on the stock.

  • Lilly widens its edge with cost and heart data Lilly released a study suggesting Zepbound offsets much of its cost by lowering other healthcare spending, and won FDA approval for Mounjaro to cut heart attack and stroke risk. Both strengthen Lilly's case for payer coverage and doctors' prescriptions, pulling demand and pricing power away from Novo.

    These new Lilly developments sharpen the competitive gap that has been pressuring Novo's shares.

  • Pipeline progress: LX9851 milestone and AWS AI deal Novo hit a clinical milestone on first-in-class oral obesity drug LX9851, adding a new mechanism to its pipeline, and expanded its AWS partnership to use AI and cloud computing to speed drug discovery. These are early-stage, but they help rebuild the pipeline after recent trial failures.

    New pipeline and technology steps address Novo's biggest weakness — a thin pipeline after setbacks — supporting long-term confidence.

▼3▲1

Novo's oral GLP-1 edge erodes as Lilly's pill arrives and sales stall

  • Lilly's Foundayo approved in UK, ending Novo's oral GLP-1 exclusivity Eli Lilly's once-daily weight-loss pill Foundayo won UK approval for obesity and type 2 diabetes, ending Novo's run as the only oral GLP-1 there. Foundayo is easier to take and priced lower, so it can pull patients and pricing power away from Novo's oral Wegovy.

    This is the period's clearest new competitive blow to Novo's key growth product.

  • Lilly's GLP-1 sales surge while Novo's Ozempic and Wegovy stall Lilly's Mounjaro and Zepbound sales jumped 91% and 46%, while Novo's Ozempic and injectable Wegovy were essentially flat. Lilly's oral Foundayo is also gaining US payer coverage, and smaller rivals are advancing their own pills, so Novo keeps losing ground in the market it once led.

    It shows the underlying demand shift that drives Novo's revenue outlook and stock.

  • Novo launches once-weekly insulin Awiqli in the US Awiqli, the first once-weekly basal insulin for type 2 diabetes, is now available across the US, cutting injections from seven a week to one. It adds a new, convenient product to Novo's diabetes business, though its sales will stay modest next to the much larger GLP-1 franchise.

    It is a genuinely new product launch that broadens Novo's diabetes revenue beyond weight-loss drugs.

  • Wegovy pill sales miss and costs rise, denting confidence Novo raised its annual guidance, but its oral Wegovy sales of 3.22 billion kroner fell short of the 3.33 billion expected, and shares dropped about 6%. Investors worry the pill launch is not yet offsetting pressure on older drugs, and a broker cut its price target after a messy quarter.

    It captures the market's negative reaction to Novo's latest numbers and guidance.

▲2▼1

Novo's oral Wegovy shines but Lilly's lead and pipeline stumbles weigh

  • Oral Wegovy prescriptions top 5 million, CEO says market not winner-take-all Novo's once-daily Wegovy pill has surpassed 5 million prescriptions since its early-2026 launch, mostly reaching patients who never tried injections. CEO Mike Doustdar says the obesity market will be segmented, not winner-take-all, and oral Wegovy already holds about 90% of the oral GLP-1 market. This supports future sales and investor confidence.

    Shows strong demand for Novo's new pill and management's confidence, a positive counterweight to competitive fears.

  • Novo partners with AWS for AI-driven drug discovery Novo Nordisk teamed up with Amazon Web Services to use artificial intelligence and cloud computing to speed up drug discovery, creating a London innovation hub. This could make Novo's research more efficient and help refill its pipeline after recent setbacks, supporting the stock by improving long-term growth prospects.

    A new partnership that could improve R&D productivity, addressing a key investor concern about pipeline weakness.

  • Lilly's UK approval of Foundayo and Amazon's $50 Medicare program add pressure Eli Lilly won UK approval for its once-daily weight-loss pill Foundayo, its first outside the US, and Amazon Pharmacy launched a $50 per month Medicare weight-loss drug program including Novo and Lilly medicines. These expand cheaper, convenient options and could shift demand and pricing away from Novo's injectables.

    New competitive and pricing developments that directly threaten Novo's market share and pricing power.

▼3▲1

Novo's Q2: raised outlook, but pipeline and competition sting

  • CagriSema flops vs Lilly's Zepbound Novo's next-generation obesity drug CagriSema failed to match Eli Lilly's Zepbound in a head-to-head trial for blood sugar control. This removes a key hoped-for growth driver and keeps Novo a step behind its biggest rival, weighing on the stock.

    This is a new pipeline setback that directly threatens Novo's future obesity franchise.

  • Oral Wegovy sales miss estimates Sales of Novo's new oral Wegovy pill came in slightly below analyst expectations, even as the company raised its full-year outlook. The miss suggests the launch is not yet offsetting pressure on older drugs, disappointing investors.

    This is a fresh demand signal for Novo's key new product and a reason shares fell despite raised guidance.

  • Lilly widens its lead with surging sales Eli Lilly's Mounjaro and Zepbound posted blowout quarterly sales, and its new oral pill Foundayo is gaining rapid traction. Lilly now treats about 10% of the US obesity population, making it harder for Novo to regain market share.

    This shows the competitive gap widening, a core force behind Novo's weak stock performance.

  • Legal wins protect semaglutide franchise Novo won a Dutch court injunction stopping a compounded semaglutide nasal spray, and a US judge dismissed an antitrust lawsuit over compounded GLP-1 access. These rulings defend Novo's patents and distribution, supporting its pricing power and stock.

    These are new legal victories that remove threats to Novo's core drug franchise.

July 2026
▲2▼2

Novo mixed in July: oral Wegovy EU approval, Medicare launch, but pipeline setback and Lilly lead

  • Medicare GLP-1 Bridge program launched Medicare's GLP-1 Bridge program launched, expanding access to Wegovy for many older Americans. This should boost demand for Novo's obesity drug and support future sales growth.

    New program launch expands market access, a key positive for Novo's revenue outlook.

  • EU approves once-daily oral Wegovy The EU approved once-daily oral Wegovy, giving patients a pill option instead of injections. This could improve convenience and uptake, strengthening Novo's position in Europe.

    New regulatory approval opens a new delivery format in a major market.

  • Ziltivekimab fails Phase 3, shares drop 10% Novo's drug ziltivekimab failed a late-stage trial, sending shares down 10%. This setback removes a potential future growth driver and highlights pipeline risks beyond obesity.

    Major pipeline failure directly caused a sharp share price drop.

  • Eli Lilly leads with 60% obesity market share Eli Lilly now holds 60% of the obesity market and has a strong pipeline including retatrutide. Novo faces intensifying competition, pressuring its market share and pricing power.

    Competitive dynamics are a key negative driver for Novo's stock.

▼3

Novo's heart drug fails; Lilly dominates as tariffs and Q2 loom

  • Heart drug ziltivekimab fails Phase 3 trial Novo's experimental heart drug ziltivekimab failed to reduce heart attacks and strokes in a large Phase 3 trial, sending the stock down about 10%. This removes a hoped-for new growth driver and shows pipeline setbacks beyond weight loss, hurting investor confidence.

    This is the single biggest new event of the period and directly caused a sharp share price drop.

  • Trump tariffs threaten Novo's drug exports Trump announced phased tariffs on generic drug imports, up to 200% by 2029, and new 10-12.5% tariffs on most trading partners. As a major EU drug exporter, Novo faces higher costs and trade uncertainty, weighing on the stock.

    New tariff policy directly targets pharmaceuticals and Novo's export model, a fresh negative force.

  • Lilly's 60% obesity market share pressures Novo Eli Lilly now controls 60% of the global obesity drug market, with its stock up 58% while Novo's fell 5%. Novo's next-gen drug CagriSema trails Lilly's Zepbound in efficacy, and Lilly's retatrutide looks even stronger, keeping Novo a step behind.

    This crystallizes the competitive gap that is the core long-term drag on Novo's valuation.

  • Q2 earnings ahead; Crux deal expands Wegovy access Novo reports Q2 on August 5 with Ozempic and Wegovy under pressure from weaker prescriptions and Medicaid coverage cuts. Offsetting this, a new Crux partnership aims to widen US employer access to Wegovy, supporting demand.

    The upcoming earnings and the new access deal are the main near-term swing factors for the stock.

▲3▼1

Novo's oral Wegovy wins EU approval, but Lilly's pipeline and price cuts pressure

  • EU approves once-daily Wegovy pill Novo won EU approval for its once-daily Wegovy pill, opening the oral obesity market across Europe. This expands access to a huge patient pool and gives Novo a first-mover edge over rivals, supporting future sales and the stock.

    New regulatory approval directly expands Novo's market and revenue potential.

  • Novo sues Eli Lilly over misleading ads Novo sued Eli Lilly, claiming its ads unfairly compare high-dose Lilly drugs to low-dose Novo drugs. If successful, it could curb Lilly's marketing and level the playing field, helping Novo's competitive position and investor sentiment.

    New legal action could reduce competitive pressure from Lilly's advertising.

  • China launch of once-weekly Kyinsu Novo's once-weekly insulin/GLP-1 combo Kyinsu launched in China, the first market globally. This innovative therapy reduces injections and could capture significant demand in China's large diabetes market, adding a new revenue stream.

    New product launch in a major market expands Novo's commercial reach.

  • Lilly's next-gen obesity drug advances Eli Lilly plans to file its triple-action obesity drug retatrutide in early 2027, showing up to 22.6% weight loss. This threatens Novo's market share with potentially superior efficacy, keeping competitive pressure high and weighing on the stock.

    New pipeline threat from Lilly could erode Novo's future market position.

▲2▼2

Novo's GLP-1 pill demand slows, but China access and new delivery tech offer support

  • US GLP-1 pill demand slows Deutsche Bank's weekly prescription tracker showed the Wegovy pill losing momentum, with the injectable and Rybelsus also expected to decline this year. This directly hits Novo's biggest growth driver, making investors worry about future sales and pushing the stock down.

    This is the most direct new negative for Novo's revenue and explains the period's share price dip.

  • China adds semaglutide to essential medicines list China's new National Essential Medicines List includes Novo's semaglutide injection, effective September 2026. This opens the door to public hospitals and government-backed demand across China, a huge market, which should lift long-term sales and support the stock.

    A new regulatory win that expands Novo's addressable market in a major region.

  • New delivery formats and label updates Novo partnered with Vivani on a semaglutide implant and updated Wegovy's Singapore label with STEP UP data showing 21% average weight loss. These broaden how the drug can be used and reinforce its effectiveness, helping Novo stand out in a crowded market.

    Shows Novo innovating beyond pills and injections, which can attract more patients and investors.

  • Competition and valuation concerns persist Viking's VK2735 showed faster weight loss in trials, Eli Lilly's Foundayo pill and $27 billion manufacturing push threaten a price war, and one analysis called Novo 12.6% overvalued. These keep pressure on Novo's market share and stock price.

    Highlights the main counterweight to Novo's positive news: rivals are advancing and the stock may be fully valued.

▲2▼1

Medicare GLP-1 launch and analyst upgrade offset cost-cut pressure

  • Medicare GLP-1 Bridge program goes live Medicare's GLP-1 Bridge program launched July 1, giving eligible seniors access to Wegovy for a $50 monthly copay. This opens a huge new patient pool, likely lifting demand and sales for Novo Nordisk. However, rival Eli Lilly's drugs are also covered at the same price, so competition remains intense.

    This is a major new event that directly expands the market for Novo's key obesity drug.

  • Nordea upgrades Novo Nordisk to Buy Nordea upgraded Novo Nordisk from Hold to Buy with a DKK 350 price target, implying 10% upside. The analyst expects strong sales of the Wegovy pill and positive near-term news. Upgrades can boost investor confidence and attract buyers, pushing the share price higher.

    A fresh analyst upgrade with a specific price target can directly influence investor sentiment and demand for the stock.

  • Novo asks suppliers for discounts to cut costs Novo Nordisk is asking suppliers for discounts to lower costs, following 9,000 job cuts. This signals financial pressure as the company tries to regain leadership in the weight-loss market. Cost-cutting may help margins long-term, but it highlights competitive struggles and could weigh on the stock.

    This new development reveals underlying financial strain and competitive pressure, which can negatively affect investor perception.

  • Competitive landscape and AI drug discovery Novo faces fierce competition from Eli Lilly's tirzepatide and new oral Foundayo, with Lilly leading the GLP-1 market. Meanwhile, AI is transforming drug discovery, and Novo's GLP-1 portfolio reached $34.6 billion in revenue, showing strong demand. The net effect is mixed: competitive pressure versus solid sales and innovation potential.

    This captures the ongoing competitive threat and the positive demand signal, providing a balanced view of forces affecting the stock.

Q2 2026
▲2▼2

Oral Wegovy gains offset by data breach and Lilly competition

  • Oral Wegovy pill captures one-third of prescriptions Novo's oral Wegovy pill captured one-third of Wegovy prescriptions and reached 3 million scripts, outpacing the injectable launch. The UK approved it first in Europe, and Japan approved Wegovy for MASH, expanding indications.

    This shows strong demand for Novo's new oral obesity drug, a key growth driver.

  • Medicare and CVS programs to widen access Medicare's GLP-1 Bridge program and CVS virtual visits should widen access to obesity drugs, potentially lifting demand for Novo's products.

    These programs could increase patient access and sales for Novo's GLP-1 drugs.

  • Patient data breach and cyber extortion A clinical trial patient data breach raised regulatory and reputational concerns, while a cyber extortion group claims to have stolen over a terabyte of drug research, trial data, and AI models, demanding $25 million.

    This poses regulatory and reputational risks that could hurt investor confidence.

  • Eli Lilly widens lead; US Ozempic sales fall 14% Eli Lilly widened its lead at the ADA conference, Novo's US Ozempic sales fell 14%, and a 50% Wegovy price cut looms, underscoring intensifying competition.

    This highlights competitive pressures and pricing challenges that could weigh on Novo's revenue.

June 2026
▲2▼2

Oral Wegovy gains offset by data breach and Lilly competition

  • Oral Wegovy pill captures one-third of prescriptions Novo's oral Wegovy pill captured one-third of Wegovy prescriptions and reached 3 million scripts, outpacing the injectable launch. The UK approved it first in Europe, and Japan approved Wegovy for MASH, expanding indications.

    This shows strong demand for Novo's new oral obesity drug, a key growth driver.

  • Medicare and CVS programs to widen access Medicare's GLP-1 Bridge program and CVS virtual visits should widen access to obesity drugs, potentially lifting demand for Novo's products.

    These programs could increase patient access and sales for Novo's GLP-1 drugs.

  • Patient data breach and cyber extortion A clinical trial patient data breach raised regulatory and reputational concerns, while a cyber extortion group claims to have stolen over a terabyte of drug research, trial data, and AI models, demanding $25 million.

    This poses regulatory and reputational risks that could hurt investor confidence.

  • Eli Lilly widens lead; US Ozempic sales fall 14% Eli Lilly widened its lead at the ADA conference, Novo's US Ozempic sales fell 14%, and a 50% Wegovy price cut looms, underscoring intensifying competition.

    This highlights competitive pressures and pricing challenges that could weigh on Novo's revenue.

▲2▼2

Oral Wegovy demand surges, but competition and cyber theft weigh

  • Oral Wegovy hits 3 million prescriptions The new Wegovy pill reached 3 million prescriptions, outpacing the injectable launch. This shows strong patient demand and a first-mover edge over Eli Lilly's less effective oral drug, supporting future revenue growth.

    This is a major new demand milestone that directly boosts Novo's sales outlook.

  • Medicare and CVS expand GLP-1 access The Medicare GLP-1 Bridge program starts July 2026 with a $50 monthly copay, covering Novo's Wegovy injection and tablets. CVS also launched $49 virtual visits for prescriptions. These widen access and should lift demand.

    New government and retail programs lower cost barriers, expanding the patient pool for Novo's drugs.

  • Cyber extortion group claims massive data theft Hackers claim to have stolen over a terabyte of Novo's drug research, trial data, and AI models, demanding $25 million. This threatens intellectual property and could lead to fines and reputational damage, weighing on the stock.

    The breach is a new negative event that raises regulatory and competitive risks for Novo.

  • Eli Lilly widens lead at ADA conference Analysts declared Eli Lilly the clear winner at the ADA meeting, with strong data on its obesity drugs. Novo's US Ozempic sales fell 14% and a 50% Wegovy price cut looms, highlighting competitive pressure.

    This underscores Novo's competitive struggles and pricing headwinds, which could keep the stock under pressure.

▲3▼1

Novo Nordisk: UK and Japan approvals, oral Wegovy surge, but data breach and rivals loom

  • Clinical trial data breach raises regulatory and reputational risk Novo Nordisk disclosed a patient data breach in its clinical trials, which could lead to investigations, fines, and stricter data rules. This adds uncertainty and potential costs, weighing on the share price, especially as supply constraints for GLP-1 drugs already limit growth.

    This is a new negative event that could hurt the company's reputation and finances, directly affecting investor sentiment.

  • UK approves Wegovy pill, first in Europe The UK became the first European country to approve an oral version of Wegovy for obesity. This opens a new market and offers patients a non-injection option, potentially boosting sales and market share as Novo Nordisk expands its obesity franchise.

    A new regulatory approval expands the addressable market and provides a competitive edge, driving future revenue growth.

  • Oral Wegovy captures one-third of total Wegovy prescriptions By May, the oral form of Wegovy made up about one-third of all Wegovy prescriptions, with 159,000 weekly prescriptions and 40% of new prescriptions. This shows strong patient adoption, which supports revenue growth and offsets some pricing pressure.

    Strong adoption of a new product format indicates robust demand and successful commercialization, a key driver for the stock.

  • Japan approves Wegovy for MASH, expanding its use Japan granted its first approval for Wegovy to treat MASH, a liver disease, based on positive trial data. This adds a new indication, widening the patient pool and reinforcing Wegovy's versatility, which could lead to higher sales and strengthen Novo Nordisk's position.

    A new indication expands the market for Wegovy beyond obesity, providing additional growth opportunities.

Novartis AG (NOVN.SW)

Q3 2026
▲2▼2

Novartis Q3: new drugs and deals offset generic hit and pipeline setbacks

  • New drug approvals and acquisition EU approved Itvisma gene therapy and FDA fully approved Fabhalta for kidney disease. Novartis also bought Myricx Bio for $1.5 billion, adding new treatments to its portfolio.

    These approvals and the acquisition are new positive events that can drive future sales and growth.

  • Earnings beat and pipeline progress Q2 earnings beat expectations with sales returning to growth. Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing, and licensing deals worth up to $8.1 billion plus Sironax acquisition signaled continued innovation investment.

    Earnings beat and pipeline advancements are new positive developments that support investor confidence.

  • Entresto sales plunge on generics Entresto sales plunged 50% due to generic competition, a $4 billion annual hit. This major revenue loss weighs on the stock.

    This is a new negative event that directly impacts Novartis's revenue and profitability.

  • Pipeline setbacks and governance concerns CAR-T trials paused after three deaths; pelacarsen and del-desiran failed late-stage trials; rifonebart was halted. UBS turned cautious, and top shareholder Artisan Partners demanded a board overhaul amid $39.4 billion net debt and governance concerns.

    These new negative events raise safety, efficacy, and governance issues that can hurt investor sentiment.

September 2026
▼2▲1

Pipeline failures and governance pressure hit Novartis in September

  • Late-stage trial failures Pelacarsen and del-desiran failed late-stage trials, erasing billions in potential revenue and market value, while ALS drug rifonebart was halted. These setbacks hurt sentiment and raised doubts about the pipeline.

    Major negative news that directly impacted investor confidence and valuation.

  • Governance pressure from top shareholder Top shareholder Artisan Partners demanded a board overhaul over dealmaking, with net debt at $39.4 billion and eight shareholders raising concerns. This adds uncertainty about strategy and capital allocation.

    Governance issues can weigh on stock price and investor trust.

  • Pipeline wins and licensing deals Remibrutinib showed best-in-class potential in MS, Cosentyx won EU backing for polymyalgia rheumatica, and Novartis signed licensing deals worth up to $8.1 billion plus acquired Sironax's brain-delivery platform, signaling continued investment in innovation.

    Positive pipeline news and deals support future growth despite recent failures.

Latest
▲2▼2

Novartis adds two big pipeline deals; board pressure and CAR-T pause persist

  • Novartis licenses two new pipeline assets in deals worth up to $8.1 billion Novartis signed a radioligand therapy license with BoomRay (up to $900 million) and an mRNA T-cell engager deal with Abogen (up to $7.2 billion). These add new cancer and autoimmune candidates, showing Novartis can still attract outside innovation and giving investors fresh growth hopes after recent trial failures.

    These are the period's only new positive events and directly counter the pipeline-failure narrative that has weighed on the stock.

  • Artisan Partners publicly demands board shake-up over deal oversight Top-20 shareholder Artisan Partners called for a board overhaul after trial failures wiped out $30 billion in market value. Eight shareholders have raised concerns about Novartis' acquisition strategy. This governance pressure keeps uncertainty high and can weigh on the shares until management responds.

    It is a new escalation of shareholder activism that directly questions Novartis' dealmaking and board, a key overhang on the stock.

  • CAR-T trial pause after three patient deaths continues to raise safety concerns Novartis paused eight rap-cel CAR-T trials in autoimmune and neurological diseases after three deaths from a severe immune reaction. The disclosure came only after an analyst noticed the halted trials. This adds regulatory and safety risk, delaying a promising new treatment area and weighing on sentiment.

    It is a new negative safety event that adds to Novartis' pipeline setbacks and can pressure the share price until reviews clear.

  • EU panel backs Cosentyx for polymyalgia rheumatica, expanding a key drug A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, adding sales for an already marketed drug and offering a modest lift.

    It is a new regulatory win that expands an existing blockbuster into a new indication, supporting near-term revenue growth.

▲2▼2

Novartis hit by three trial failures; pipeline doubts deepen

  • ALS drug rifonebart halted after mid-stage failure Novartis stopped developing its ALS drug rifonebart after it failed its main and secondary goals in a mid-stage trial of 251 patients. This adds to a string of pipeline setbacks, making investors doubt Novartis's ability to turn research spending into new products and pressuring the shares.

    New pipeline failure that directly adds to negative sentiment and future growth doubts.

  • Novartis buys Sironax brain-delivery platform for $125 million Novartis exercised an option to acquire Sironax's brain-delivery technology for $125 million, gaining a way to get large drugs across the blood-brain barrier. This modestly strengthens its neurology pipeline and shows it is still investing in new science despite recent failures.

    New deal that shows continued pipeline investment and a small positive counterweight.

  • EU panel backs Cosentyx for polymyalgia rheumatica A European Medicines Agency committee recommended approving Cosentyx for polymyalgia rheumatica, a painful inflammatory condition. If the European Commission agrees, it would be the first IL-17A inhibitor cleared for this disease in Europe, expanding sales for an already marketed drug and offering a small lift.

    New regulatory win that broadens an existing product's label and provides a positive offset.

  • Board pressure and $39.4 billion net debt raise capital concerns After the del-desiran failure, top shareholder Artisan Partners demanded a board overhaul, and reports highlighted that Novartis spent over $30 billion on deals, pushing net debt to $39.4 billion. This raises doubts about dealmaking discipline and leaves less room for error, weighing on the stock.

    New details on activist pressure and balance-sheet strain that affect investor confidence.

▼3▲1

Novartis hit by two trial failures, board pressure; MS drug offers hope

  • Pelacarsen heart drug fails, wiping out $6B opportunity Novartis's cholesterol drug pelacarsen failed a final-stage trial, losing a potential $3–6 billion-a-year seller. The news sent shares down 3.3% and removed a key growth driver, making investors question the company's pipeline.

    This is a major pipeline failure that directly hurt the stock and shifts focus to remaining drugs.

  • Muscle-wasting drug del-desiran fails, shares plunge 10–13% The lead asset from Novartis's $12 billion Avidity acquisition failed its pivotal trial, erasing about CHF24–30 billion in market value. This is the third setback in a week and raises doubts about the company's deal-making and pipeline.

    This is the biggest new negative event, causing a record share drop and directly impacting valuation.

  • Top shareholder Artisan Partners demands board shake-up After the record share fall, Artisan Partners publicly urged Novartis to overhaul its board and deal team, citing failed acquisitions. This adds governance and reputational pressure, which can weigh on the stock until management responds.

    This is a new activist investor move that increases uncertainty and could force changes, affecting investor confidence.

  • Remibrutinib beats Sanofi's Aubagio in two late-stage MS trials Novartis's oral MS drug remibrutinib outperformed an older treatment, showing best-in-class potential with no liver-safety issues. Analysts see up to $9 billion in peak sales, offering a bright spot amid recent failures and supporting future growth.

    This is the main positive counterweight, showing pipeline strength and potential to offset losses.

August 2026
▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

  • CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

    A major safety setback that directly threatens a key pipeline and investor confidence.

  • Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

    The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

  • Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

    A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

  • Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

    A new partnership that supports future product lifecycles and is not already covered.

▲2▼2

Novartis pipeline swings: MS win, CAR-T pause, heart drug miss

  • CAR-T trial halt after three deaths Novartis paused eight CAR-T trials for autoimmune and neurological diseases after three patients died from a severe immune reaction. This raises safety and regulatory risk, delays a promising new treatment area, and can weigh on the share price until reviews clear.

    A major safety setback that directly threatens a key pipeline and investor confidence.

  • Remibrutinib wins two Phase 3 MS trials The oral drug remibrutinib beat teriflunomide on relapses and brain lesions in two late-stage MS trials, with no liver-safety worry. This opens a large new market and drove the stock up about 6%, though the shares already trade above many value estimates.

    The period's biggest positive catalyst, with clear efficacy and a large commercial opportunity.

  • Pelacarsen fails main heart trial goal Partner Ionis said Novartis' pelacarsen lowered Lp(a) levels but did not reduce major heart events versus placebo in a Phase 3 trial. This removes a potential growth driver for a common inherited heart risk, hurting sentiment on Novartis' cardiovascular pipeline.

    A late-stage failure that erases a hoped-for new revenue source and dents pipeline credibility.

  • Alteogen deal for subcutaneous versions Novartis signed an option and license deal with Alteogen to turn some intravenous biologics into easier subcutaneous shots, with up to $3.2 billion in potential payments. This could extend the life and convenience of existing products, a modest positive for the pipeline.

    A new partnership that supports future product lifecycles and is not already covered.

July 2026
▲4▼2

Novartis pipeline wins and earnings beat offset Entresto decline

  • EU approval for Itvisma gene therapy Novartis received EU approval for its Itvisma gene therapy, adding a new treatment option and reinforcing its position in advanced therapies. This expands the company's portfolio and offers a potential new revenue stream.

    This is a new regulatory win that supports future growth.

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval for Fabhalta in kidney disease, transitioning from accelerated approval. This validates the drug's efficacy and allows broader marketing, potentially boosting sales in a new indication.

    This is a new regulatory milestone that could drive revenue.

  • $1.5B Myricx Bio acquisition Novartis acquired Myricx Bio for $1.5 billion, adding a new asset to its pipeline. This strategic move aims to bolster future growth through external innovation.

    This is a new acquisition that expands the pipeline.

  • Q2 earnings beat with sales returning to growth Novartis reported Q2 earnings that beat expectations, with sales returning to growth despite Entresto's decline. This shows resilience and operational execution, reassuring investors about the company's trajectory.

    This is a new financial result that positively surprised the market.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% as generic competition entered the market, resulting in a $4 billion annual revenue hit. This significant loss pressures overall growth and profitability.

    This is a new negative development impacting financials.

  • UBS turns cautious on Novartis relative to peers UBS downgraded its view on Novartis, citing relative underperformance compared to AstraZeneca and Roche. This cautious stance may limit upside and affect investor sentiment.

    This is a new analyst action that could weigh on the stock.

  • High-stakes late-stage trials could add $10B+ but face failure risk Three late-stage trials (pelacarsen, remibrutinib, del-desiran) could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates meaningful pipeline uncertainty.

    This is a new analyst warning about pipeline risk.

▲2▼1

Novartis wins FDA label expansions, Q2 beat, but Entresto cliff and pipeline risk loom

  • FDA full approval for Fabhalta in kidney disease The FDA granted full approval to Fabhalta for slowing kidney decline in IgA nephropathy, upgrading it from accelerated approval. This expands the market for a first-in-class oral drug and adds a new growth driver, supporting the stock.

    This is a new regulatory win that directly boosts Novartis's revenue outlook.

  • Q2 earnings beat and sales return to growth Novartis beat second-quarter profit and sales estimates, with key brands like Kisqali and Pluvicto growing strongly. Sales returned to growth despite Entresto's 50% decline, reassuring investors and lifting the stock.

    The earnings beat is a new event that shows the company's core business is performing better than expected.

  • Entresto sales plunge 50% on generics Entresto sales fell 50% to $1.18 billion as cheaper generics entered the market, a $4 billion annual revenue hit. This drags on overall growth and pressures the stock, though newer drugs are offsetting some of the loss.

    This is a major negative force that explains why Novartis's growth is muted and why the stock faces a headwind.

  • Pipeline bets face high-stakes trial readouts Novartis is relying on three late-stage trials (pelacarsen, remibrutinib, del-desiran) that could add over $10 billion in sales, but Goldman Sachs warns the stock could suffer if at least two fail. This creates uncertainty around future growth.

    This highlights the key risk and potential reward that will drive the stock's longer-term direction.

▲3▼1

Novartis advances gene therapy and oncology pipeline, but UBS turns cautious

  • EU approval for Itvisma gene therapy Novartis won European Commission approval for Itvisma, a one-time gene replacement therapy for spinal muscular atrophy in patients aged 2 and older. This expands its approved product portfolio in Europe and opens a new revenue stream, supporting the stock.

    This is a concrete regulatory win that directly adds a new approved product and potential sales.

  • Acquisition of Myricx Bio for up to $1.5B Novartis agreed to buy UK biotech Myricx Bio for up to $1.5 billion, gaining a first-in-class antibody-drug conjugate payload platform and two lead assets. This strengthens its oncology pipeline and shows commitment to high-growth areas, a positive for the stock.

    This is a major strategic deal that bolsters the pipeline and signals growth investment.

  • ianalumab positioned in growing markets Novartis' ianalumab is highlighted as a key late-stage candidate in warm autoimmune hemolytic anemia and systemic lupus erythematosus, both large markets with no approved therapies. Phase III results are expected in 2027, offering a potential future growth driver.

    This points to a significant pipeline opportunity that could drive future revenue.

  • UBS cautious on Novartis UBS reiterated an overweight view on European pharma but was more cautious on Novartis, preferring peers like AstraZeneca and Roche. This relative caution may weigh on sentiment and limit the stock's upside compared to sector peers.

    This is a direct analyst opinion that could influence investor perception and relative performance.

Q2 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

June 2026
▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

▲3▼1

Novartis pipeline wins offset patent loss in radioligand therapy

  • Patent loss opens door to competitor in key cancer therapy A US court invalidated Novartis patents on its Lutathera radioligand therapy, allowing Curium to launch a competing version. This threatens future sales of a key product, weighing on the stock.

    This is a new negative regulatory event that directly challenges Novartis's radioligand franchise.

  • Positive Phase III data for Rhapsido in chronic inducible urticaria Novartis reported that Rhapsido met primary endpoints in a Phase III trial for chronic inducible urticaria, becoming the first to show efficacy in this condition. This supports a potential new growth driver.

    New clinical success expands the pipeline and boosts confidence in future revenue.

  • Early promise for del-brax in rare muscle disease Novartis's experimental drug del-brax showed promise in an early trial for FSHD, lowering disease markers and muscle damage. If approved, it could be the first disease-modifying treatment, adding a new rare-disease asset.

    New positive trial data for a potential first-in-class therapy supports long-term growth.

  • Oncology deals and market growth outlook Novartis announced two oncology partnerships (Antares, Orionis) worth up to $3.3 billion and a market report projected its radioligand therapy sales to reach $30 billion by 2034. These reinforce its pipeline and leadership in a high-growth area.

    New deals and market forecast highlight Novartis's strategy to offset patent losses and drive future sales.

© 2026 MarketIVWhy